{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:08:46Z","timestamp":1784804926509,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18fk0210020h0002"],"award-info":[{"award-number":["18fk0210020h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pruritus is a common symptom seen in patients with chronic liver disease. However, frequency and severity of pruritus in patients with chronic liver disease is unclear. We investigated frequency, severity and predictive factors of pruritus in these patients from a large cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 2477 patients with chronic liver disease without allergies or skin diseases were investigated for itch frequency and severity. Itch severity was self-assessed using pruritus scores using the numerical rating scale (NRS). Multivariate regression analysis was performed to identify factors associated with pruritus. Serum autotaxin levels were measured in patients with primary biliary cholangitis (PBC), and the relationship to liver fibrosis and pruritus was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The frequency of pruritus in patients with chronic liver disease was significantly higher than in subjects without liver disease (29.8 and 16.2%, respectively,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). NRS was high in patients with chronic liver disease, especially in those with PBC, as is generally expected. Multivariate analysis identified lower albumin, higher eosinophil count, and etiology of PBC as independent factors associated with severe pruritus (\u22655 points of NRS). In patients with PBC, serum autotaxin levels were significantly correlated with liver fibrosis markers such as platelet count and liver stiffness, and hepatobiliary enzymes such as total bilirubin, aspartate aminotransferase and alkaline phosphatase. However, no significant correlations between serum autotaxin levels and frequency and severity of pruritus were observed in patients with PBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The frequency of pruritus was high in patients with chronic liver disease. Reduction of liver function is associated with severe pruritus based on the large number of patients with chronic liver disease. Serum autotaxin is useful for assessing liver fibrosis and severity of cholangitis; however, it is not a predictive marker for severe pruritus in patients with PBC.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-019-1092-z","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T12:17:37Z","timestamp":1572005857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis"],"prefix":"10.1186","volume":"19","author":[{"given":"Hatsue","family":"Fujino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0745-991X","authenticated-orcid":false,"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Morio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(96)04328-0","volume":"348","author":"MW Greaves","year":"1996","unstructured":"Greaves MW, Wall PD. Pathophysiology of itching. Lancet. 1996;348:938\u201340.","journal-title":"Lancet"},{"key":"1092_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1089-3261(03)00105-3","volume":"7","author":"NV Bergasa","year":"2003","unstructured":"Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879\u2013900.","journal-title":"Clin Liver Dis"},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1572-0241.2000.01774.x","volume":"95","author":"ZM Younossi","year":"2000","unstructured":"Younossi ZM, Kiwi ML, Boparai N, et al. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol. 2000;95:497\u2013502.","journal-title":"Am J Gastroenterol"},{"key":"1092_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/hep.510290450","volume":"29","author":"EA Jones","year":"1999","unstructured":"Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003\u20136.","journal-title":"Hepatology"},{"key":"1092_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejphar.2003.08.007","volume":"477","author":"H Umeuchi","year":"2003","unstructured":"Umeuchi H, Togashi Y, Honda T, et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol. 2003;477:29\u201335.","journal-title":"Eur J Pharmacol"},{"key":"1092_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mehy.2017.11.002","volume":"110","author":"NV Bergasa","year":"2018","unstructured":"Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Med Hypotheses. 2018;110:86\u20139.","journal-title":"Med Hypotheses"},{"key":"1092_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0165-6147(98)01169-9","volume":"19","author":"ZZ Pan","year":"1998","unstructured":"Pan ZZ. mu-opposing actions of kappa-opioid receptor. Trens Pharmacol Sci. 1998;19:94\u20138.","journal-title":"Trens Pharmacol Sci"},{"key":"1092_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/hepr.12830","volume":"47","author":"H Kumada","year":"2017","unstructured":"Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patient with chronic liver disease with refractory pruritus: A randomized double-blind trial. Hepatol Res. 2017;47:972\u201382.","journal-title":"Hepatol Res"},{"key":"1092_CR9","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/S0021-9258(18)45911-X","volume":"267","author":"ML Stracke","year":"1992","unstructured":"Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992;267:2524\u20139.","journal-title":"J Biol Chem"},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"39436","DOI":"10.1074\/jbc.M205623200","volume":"277","author":"A Tokumura","year":"2002","unstructured":"Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002;277:39436\u201339,442.","journal-title":"J Biol Chem"},{"key":"1092_CR11","doi-asserted-by":"publisher","first-page":"46705","DOI":"10.1038\/srep46705","volume":"7","author":"T Yamazaki","year":"2017","unstructured":"Yamazaki T, Joshita S, Umemura T, et al. Association of Serum autotaxin levels with liver fibrosis in patients with chronic hepatitis C. Sci Rep. 2017;7:46705.","journal-title":"Sci Rep"},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cca.2011.03.014","volume":"412","author":"H Nakagawa","year":"2011","unstructured":"Nakagawa H, Ikeda H, Nakamura K, et al. Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta. 2011;412:1201\u20136.","journal-title":"Clin Chim Acta"},{"key":"1092_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/hepr.12997","volume":"48","author":"S Joshita","year":"2018","unstructured":"Joshita S, Ichikawa Y, Umemura T, et al. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatol Res. 2018;48:275\u201385.","journal-title":"Hepatol Res"},{"key":"1092_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3748\/wjg.v24.i11.1239","volume":"24","author":"N Fujimori","year":"2018","unstructured":"Fujimori N, Umemura T, Kimura T, et al. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2018;24:1239\u201349.","journal-title":"World J Gastroenterol"},{"key":"1092_CR15","doi-asserted-by":"publisher","first-page":"8159","DOI":"10.1038\/s41598-018-26531-0","volume":"8","author":"S Joshita","year":"2018","unstructured":"Joshita S, Umemura T, Usami Y, et al. Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis. Sci Rep. 2018;8:8159.","journal-title":"Sci Rep"},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","volume":"139","author":"AE Kremer","year":"2010","unstructured":"Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008\u201318.","journal-title":"Gastroenterology"},{"key":"1092_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2016","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2016;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1092_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2340\/00015555-1620","volume":"93","author":"S St\u00e4nder","year":"2013","unstructured":"St\u00e4nder S, Augustin M, Reich A, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93:509\u201314.","journal-title":"Acta Derm Venereol"},{"key":"1092_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2007.10.005","volume":"388","author":"K Nakamura","year":"2008","unstructured":"Nakamura K, Igarashi K, Ide K, et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta. 2008;388:51\u20138.","journal-title":"Clin Chim Acta"},{"key":"1092_CR20","doi-asserted-by":"publisher","first-page":"30847","DOI":"10.1038\/srep30847","volume":"6","author":"E Wunsch","year":"2016","unstructured":"Wunsch E, Krawczyk M, Milkiewicz M, et al. Serum autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver Diseases. Sci Rep. 2016;6:30847.","journal-title":"Sci Rep"},{"key":"1092_CR21","doi-asserted-by":"publisher","first-page":"E252","DOI":"10.1111\/hepr.12978","volume":"48","author":"S Oeda","year":"2018","unstructured":"Oeda S, Takahashi H, Yoshida H, et al. Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018;48:E252\u201362.","journal-title":"Hepatol Res"},{"key":"1092_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1023\/A:1018865809556","volume":"42","author":"E Lebovics","year":"1997","unstructured":"Lebovics E, Seif F, Kim D, et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci. 1997;42:1094\u20139.","journal-title":"Dig Dis Sci"},{"key":"1092_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/MEG.0000000000001159","volume":"30","author":"Y Tachi","year":"2018","unstructured":"Tachi Y, Hirai T, Kojima Y, et al. Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response. Eur J Gastroenterol Hepatol. 2018;30:1066\u201372.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1092_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1590-8658(00)80847-6","volume":"32","author":"M Bonacini","year":"2000","unstructured":"Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis. 2000;32:621\u20135.","journal-title":"Dig Liver Dis"},{"key":"1092_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2340\/00015555-0350","volume":"88","author":"E Rishe","year":"2008","unstructured":"Rishe E, Azarm A, Bergasa NV. Itch in primary biliary cirrhosis: a patients\u2019 perspective. Acta Derm Venereol. 2008;88:34\u20137.","journal-title":"Acta Derm Venereol"},{"key":"1092_CR26","doi-asserted-by":"publisher","first-page":"295891","DOI":"10.1155\/2015\/295891","volume":"2015","author":"A Bhalerao","year":"2015","unstructured":"Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract. 2015;2015:295891.","journal-title":"Dermatol Res Pract"},{"key":"1092_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/hepr.12894","volume":"48","author":"N Akuta","year":"2018","unstructured":"Akuta N, Kumada H, Fujiyama S, et al. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride. Hepatol Res. 2018;48:45\u201350.","journal-title":"Hepatol Res"},{"key":"1092_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"353","author":"MM Kaplan","year":"2005","unstructured":"Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261\u201373.","journal-title":"N Engl J Med"},{"key":"1092_CR29","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jhep.2005.12.012","volume":"44","author":"JL Newton","year":"2006","unstructured":"Newton JL, Bhala N, Burt J, Jones DE. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol. 2006;44:776\u201383.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1092-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T02:43:02Z","timestamp":1611628982000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1092-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1092-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"10 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent to participate in the study according to the process approved by the ethical committee of Hiroshima University and conforming to the ethical guidelines of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The authors declare that no patient data (details, images or videos relating to individual participants) are included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michio Imamura has received research funding from Bristol-Myers Squibb. Kazuaki Chayama has received honoraria from Bristol-Myers Squibb, MSD K.K., AbbVie Inc., Gilead Sciences and Dainippon Sumitomo Pharma and research funding from Dainippon Sumitomo Pharma, MSD K. K and AbbVie Inc..","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}